Steven Smith
Steven Smith has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Anne Moon
10Tempest Therapeutics, Brisbane, California
31 shared publications - Bruno Bastos
Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
31 shared publications - Chan C. Whiting
10Tempest Therapeutics, Brisbane, California
31 shared publications - John Powderly
Carolina BioOncology Institute, Huntersville, NC
31 shared publications - Leisha A. Emens
Department of Medicine, University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, 5117 Centre Avenue, 1.46e, Pittsburgh, PA 15213, USA
31 shared publications - Mark Yarchoan
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
31 shared publications
Latest Publications
- Open Access
- 13 November 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (11) , e70064
A randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect
TQS‐168, a first‐in‐class small‐molecule inducer of peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha gene expression, is in development for the treatment of amyotrophic lateral sclerosis. A single‐ascending‐dose (SAD) and multiple‐ascending‐dose (MAD) study of TQS‐168 was carried out in healthy male subjects to investigate safety, tolerability, pharmacokinetics (PK), food effect, and preliminary pharmacodynamic effects (PD). Since solubility enhancement could be beneficial, assessment of three formulations was incorporated into the study using an integrated rapid manufacturing and clinical testing approach. Dosing in the SAD part was initiated with a crystalline methylcellulose (MC) suspension, and then spray‐dried dispersion (SDD) and hot‐melt extrusion (HME) suspensions were evaluated. The HME and SDD formulations showed two and fourfold higher exposure than the MC suspension, respectively, and the SDD formulation was selected for progression to subsequent SAD and MAD cohorts, in which there was further investigation of the food effect on exposure in addition to assessments of safety, tolerability, PK, and PD. Cmax and AUC plasma exposures of TQS‐168 were supra‐proportional at higher doses, irrespective of formulation. Median Tmax for TQS‐168 occurred between 0.5 and 4.0 h post‐dose and occurred later with higher doses. Geometric mean half‐lives (T1/2) for TQS‐168 were independent of formulation and food, ranging from 3.2 to 10.5 h following single doses and 4.1 to 7.3 h following multiple doses. Food blunted TQS‐168 Cmax but had minimal impact on AUC. TQS‐168 was considered to be safe and generally well tolerated following single and multiple oral doses. The SDD formulation was selected for future patient studies.
- 13 November 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (11) , e70064
Open AccessA randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect
TQS‐168, a first‐in‐class small‐molecule inducer of peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha gene expression, is in development for the treatment of amyotrophic lateral sclerosis. A single‐ascending‐dose (SAD) and multiple‐ascending‐dose (MAD) study of TQS‐168 was carried out in healthy male subjects to investigate safety, tolerability, pharmacokinetics (PK), food effect, and preliminary pharmacodynamic effects (PD). Since solubility enhancement could be beneficial, assessment of three formulations was incorporated into the study using an integrated rapid manufacturing and clinical testing approach. Dosing in the SAD part was initiated with a crystalline methylcellulose (MC) suspension, and then spray‐dried dispersion (SDD) and hot‐melt extrusion (HME) suspensions were evaluated. The HME and SDD formulations showed two and fourfold higher exposure than the MC suspension, respectively, and the SDD formulation was selected for progression to subsequent SAD and MAD cohorts, in which there was further investigation of the food effect on exposure in addition to assessments of safety, tolerability, PK, and PD. Cmax and AUC plasma exposures of TQS‐168 were supra‐proportional at higher doses, irrespective of formulation. Median Tmax for TQS‐168 occurred between 0.5 and 4.0 h post‐dose and occurred later with higher doses. Geometric mean half‐lives (T1/2) for TQS‐168 were independent of formulation and food, ranging from 3.2 to 10.5 h following single doses and 4.1 to 7.3 h following multiple doses. Food blunted TQS‐168 Cmax but had minimal impact on AUC. TQS‐168 was considered to be safe and generally well tolerated following single and multiple oral doses. The SDD formulation was selected for future patient studies.
- Open Access
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
TABLE 3 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Summary of genes associated with TPST-1120 exposure levels
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 3 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Summary of genes associated with TPST-1120 exposure levels
- Open Access
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
TABLE 2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Treatment-related treatment-emergent AEs by preferred term in ≥1 patient, any grade and grade 3
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Treatment-related treatment-emergent AEs by preferred term in ≥1 patient, any grade and grade 3
- Open Access
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Summary of pharmacokinetics of 600 mg TPST-1120 twice daily as a single agent and in combination with nivolumab after single dose or at steady state (cycle 1 day 8)
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Summary of pharmacokinetics of 600 mg TPST-1120 twice daily as a single agent and in combination with nivolumab after single dose or at steady state (cycle 1 day 8)
- Open Access
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
TABLE 2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Treatment-related treatment-emergent AEs by preferred term in ≥1 patient, any grade and grade 3
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Treatment-related treatment-emergent AEs by preferred term in ≥1 patient, any grade and grade 3
- Open Access
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Monotherapy tumor control in late-line cholangiocarcinoma. Change in measurable tumor burden over time is shown for two patients with late-line cholangiocarcinoma demonstrating prolonged disease control achieved with monotherapy TPST-1120, including patient B who achieved multiple stable disease scans with serial shrinkage of tumor burden to a nadir of -13% by RECIST over a duration of 9.5 months on treatment. Prior systemic treatment for patient A included cisplatin/gemcitabine, an investigational multi-kinase inhibitor, and an investigational anti-PD-1, while patient B received carboplatin/taxol, gemcitabine, oxaliplatin/capecitabine, and an investigational anti-PD-1/indoleamine 2,3-dioxygenase 1 inhibitor combination. Both patients discontinued the most recent therapy regimen received prior to TPST-1120 treatment for progressive disease.
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Monotherapy tumor control in late-line cholangiocarcinoma. Change in measurable tumor burden over time is shown for two patients with late-line cholangiocarcinoma demonstrating prolonged disease control achieved with monotherapy TPST-1120, including patient B who achieved multiple stable disease scans with serial shrinkage of tumor burden to a nadir of -13% by RECIST over a duration of 9.5 months on treatment. Prior systemic treatment for patient A included cisplatin/gemcitabine, an investigational multi-kinase inhibitor, and an investigational anti-PD-1, while patient B received carboplatin/taxol, gemcitabine, oxaliplatin/capecitabine, and an investigational anti-PD-1/indoleamine 2,3-dioxygenase 1 inhibitor combination. Both patients discontinued the most recent therapy regimen received prior to TPST-1120 treatment for progressive disease.
- Open Access
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
A, PR in a 54-year-old female with RCC who had disease progression on prior anti-PD-1 therapy. Prior treatment included ipilimumab + nivolumab (first line), cabozantinib (second line), and everolimus (third line) with no better than SD on any regimen. She achieved a PR (−54%) after 8 weeks of treatment with TPST-1120 + nivolumab that deepened to −62% and was durable for more than 1 year. Changes in pulmonary lesions are shown in CT chest scans taken during screening and on-treatment. SD, stable disease. B, PR in an 84-year-old male with heavily pretreated extrahepatic cholangiocarcinoma. He had an initial increase in tumor burden followed by serial shrinking tumor scans before achieving a nadir of −34% and an overall response of PR at scan 4. SLD: sum of longest diameters.
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
A, PR in a 54-year-old female with RCC who had disease progression on prior anti-PD-1 therapy. Prior treatment included ipilimumab + nivolumab (first line), cabozantinib (second line), and everolimus (third line) with no better than SD on any regimen. She achieved a PR (−54%) after 8 weeks of treatment with TPST-1120 + nivolumab that deepened to −62% and was durable for more than 1 year. Changes in pulmonary lesions are shown in CT chest scans taken during screening and on-treatment. SD, stable disease. B, PR in an 84-year-old male with heavily pretreated extrahepatic cholangiocarcinoma. He had an initial increase in tumor burden followed by serial shrinking tumor scans before achieving a nadir of −34% and an overall response of PR at scan 4. SLD: sum of longest diameters.
- Open Access
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Genes differentially expressed as a function of BOR on day 8. (A) Linear discriminant analysis of Log2 fold change in expression levels of 780 genes in patients stratified based on BOR. PR: partial response; SD: stable disease; PD: progressive disease. (B) Genes that maximally discriminate between PR and PD patients enrolled in combination therapy arm. * p<0.05 by Mann-Whitney U-test.
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Genes differentially expressed as a function of BOR on day 8. (A) Linear discriminant analysis of Log2 fold change in expression levels of 780 genes in patients stratified based on BOR. PR: partial response; SD: stable disease; PD: progressive disease. (B) Genes that maximally discriminate between PR and PD patients enrolled in combination therapy arm. * p<0.05 by Mann-Whitney U-test.
- Open Access
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Additional PPAR-α Associated Genes Monitored
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Additional PPAR-α Associated Genes Monitored
- Open Access
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Elevated circulating free fatty acids (FFA) at days 57 and 85 in PR patients. Log2-fold changes in baseline normalized FFA in patients enrolled in Part 2. Samples were collected prior to TPST-1120 dose administration on day 1 of each 28-day cycle. Blue symbols: PD/SD patients; Red symbols: PR patients.
- 18 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Elevated circulating free fatty acids (FFA) at days 57 and 85 in PR patients. Log2-fold changes in baseline normalized FFA in patients enrolled in Part 2. Samples were collected prior to TPST-1120 dose administration on day 1 of each 28-day cycle. Blue symbols: PD/SD patients; Red symbols: PR patients.